Clinical Pharmacology Considerations for Development of β Lactamase Inhibitor Combination with Antibiotics

Abstract

The shrinking drug pipeline for antibacterial drugs has made it very precious to discover and develop novel drugs in this space. In this context, the recent approvals of β lactamase inhibitors with either cephalosporin or penem as combination drugs are welcome news to the community. There are number of β lactamase inhibitors with suggested partnered drugs that are currently in various stages of drug development. The focus of this manuscript is to provide some perspectives on clinical pharmacology considerations that may aid in the successful development of such combination drugs. In this regard, a broad framework which includes pharmacokinetics (PK), pharmacodynamics (PD) and PK/PD guided surrogate strategies are provided to enable an informed dosing decision of the combination agent.

Key words

antibacterial drugs - bioavailability - infectious diseases - pharmacokinetics

• References

• 1 Outterson K, Gopinathan U, Clift C. et al. Delinking investment in antibiotic research and development from sales revenues: The challenges of transforming a promising idea into reality. PLoS Med. 13: e1002043 2016;
• 2 Payne DJ, Miller LF, Findlay D. et al. Time for a change: addressing R&D and commercialization challenges for antibacterials. Philos Trans R Soc Lond B Biol Sci 370: 20140086 2015;
• 3 Brogan DM, Mossialos E. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline. Soc Sci Med. 151: 167-172 2016;
• 4 Tse BN, Adalja AA, Houchens C. et al. Challenges and opportunities of Nontraditional Approaches to Treating Bacterial Infections. Clin Infect Dis. 65: 495-500 2017;
• 5 Hauser AR, Mecsas J, Moir DT. Beyond antibiotics: New therapeutic approaches for bacterial infections. Clin Infect Dis. 63: 89-95 2016;
• 6 Dickey SW, Cheung GYC, Otto M. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 16: 457-471 2017;
• 7 Semeniuc CA, Pop CR, Rotar AM. Antibacterial activity and interactions of plant essential oil combinations against Gram-positive and Gram-negative bacteria. J Food Drug Anal. 25: 403-408 2017;
• 8 Franklyne JS, Mukherjee A, Chandrasekaran N. Essential oil micro- and nanoemulsions: promising roles in antimicrobial therapytargeting human pathogens. Lett Appl Microbiol. 63: 322-334 2016;
• 9 Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?. Clin Microbiol Infect 23: 704-712 2017;
• 10 VABOMERE™ (meropenem and vaborbactam) for injection, for intravenous use https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209776lbl.pdf. Last accessed, October 16, 2017
• 11 AVYCAZ® (ceftazidime and avibactam) for injection, for intravenous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206494s002lbl.pdf Last accessed, October 16, 2017
• 12 Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 46: 483-493 2015;
• 13 Merdjan H, Rangaraju M, Tarral A. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Clin Drug Investig 35: 307-317 2015;
• 14 Strayer AH, Gilbert DH, Pivarnik P. et al. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother 38: 2351-2356 1994;
• 15 Singh R, Kim A, Tanudra MA. et al. Pharmacokinetics/pharmacodynamics of a beta-lactam and beta-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother 70: 2618-2626 2015;
• 16 Sy SKB, Beaudoin M-E, Zhuang L. et al. In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms. J Antimicrob Chemother. 71: 1866-1880 2016;
• 17 VanScoy B, Mendes RE, Nicasio AM. et al. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother. 57: 2809-2814 2013;
• 18 Mouton JW, Punt N, Vinks AA. Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo. Antimicrob Agents Chemother 51: 3449-3451 2007;
• 19 Bhagunde P, Chang K-T, Hirsch EB. et al. A novel modeling framework to guide design of optimal dosing strategies for beta-lactamase inhibitors. Antimicrob Agents Chemother 56: 2237-2240 2012;
• 20 Mavridou E, Melchers RJB, van Mil ACHAM. et al. Pharmacodynamics of imipenem in combination with b-lactamase inhibitor MK7655 in a murine thigh model. Antimicrob Agents Chemother 59: 790-795 2015;
• 21 De Waele JJ, Lipman J, Akova M. et al. Risk factors for target non-attainment during empirical treatment with b-lactam antibiotics in critically ill patients. Int Care Med 40: 1340-1351 2014;